The Cannabis Movement

All eyes are on cannabis - it is now one of the fastest growing industries in the world, propelled by the groundswell of public demand and rapidly changing perceptions about the therapeutic potential of the cannabis plant in a wide range of conditions.

Cannabis going mainstream is the most widely anticipated trend in healthcare. International bodies such as the World Health Organization, United Nations and the European Commission have now accepted the safety and therapeutic potential of cannabis, paving the way for greater medical research and progress in legalisation of use in many countries.

History Of Cannabis

Cannabis’ medicinal properties have been known for millennia. Cannabis was first thought to have originated from Central Asia and was used by many ancient societies. In fact, indications for therapeutic use of cannabis were mentioned in the texts of the Indian Hindus, Assyrians, Greeks and Romans. Cannabis was described to have helped alleviate and treat many health ailments, including pain, depression, inflammation, appetite loss and asthma related problems.

The Endocannabnioid System

The Cannabis plant contains two of the most prominent cannabinoids; Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC). Through the Endocannabinoid System in our body, CBD and THC interact to have various effects.

The endocannabinoid system (ECS) is a complex cell-signalling system found throughout our body. It consists of three key components, including:

  • Endocannabinoids
  • Molecules created by our body
  • Receptors

Two key receptors:
CB1 - mainly found in central nervous system
CB2 - mainly found in peripheral nervous system
Endocannabinoids bind to either receptor & effects depend on where the receptor is located.
The endocannabinoid system plays a critical role in balancing many processes in our body, including immune response, appetite, sleep, et cetera.

Dawn of a new era in cannabis innovation.

Combining our deep experience in scientific research, pharmaceutical manufacturing standards and the advanced WaferiX technology, we produce breakthrough medicinal cannabis products that allow patients to benefit from the full therapeutic potential of the cannabis plant.

Voted the best CBD product in Australia

Our innovative sublingual medicinal cannabis wafers are currently supplied in Australia through a special access scheme.

Our Xativa CBD wafers have been voted the “CBD Product of the Year” in the Cannabis Industry Awards in Australia. The Cannabis Industry Awards recognise organisations and their products for innovation, excellence and impact. The awards are judged independently and transparently by a diverse panel of volunteers who are industry experts and community trailblazers, ensuring a level playing field to make the awards truly representative.

Sublingual is the preferred delivery

Medicinal cannabis is currently consumed in many different ways, most notably via ingestion of oral preparations such as tinctures, oils and capsules, and through vaporising and smoking.

Our sublingual medicinal cannabis wafers come in a discreet and convenient fixed dosage form and are the best approach for faster and more predictable absorption, hence improving outcomes.

Diverse product range to better serve patients

Through advancements in scientific research, it is now known that different cannabinoids may be more effective for certain conditions. To meet the needs of every unique patient, we have created a line of products that contain CBD, THC and CBD and THC in varying dosage levels. If recommended by their physician, patients are able to start treatment with a low dose before titrating up to a more potent dose.

The Xativa Hub is an Australian patient access gateway and an information hub for GPs and specialists to find out more about current research and treatment products available in Australia.